Form 4: Beam Therapeutics President Giuseppe Ciaramella Reports Acquisition of 35,000 Shares

Giuseppe Ciaramella, President of Beam Therapeutics, reports the acquisition of 35,000 shares of common stock through restricted stock units.

Summary

• Giuseppe Ciaramella, President of Beam Therapeutics Inc., filed a Form 4 on April 02, 2025.
• The report details a transaction on March 31, 2025, where Ciaramella acquired 35,000 shares of Beam Therapeutics' common stock.
• These shares were obtained through restricted stock units (RSUs) granted under the company's 2019 Equity Incentive Plan.
• Each RSU represents the right to receive one share of BEAM's common stock.
• The RSUs vest in four equal installments on the anniversaries of the grant date, contingent upon Ciaramella's continued service with Beam Therapeutics.
• Following the reported transaction, Ciaramella beneficially owns 197,650 shares of Beam Therapeutics' common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The RSUs vest over four years, suggesting a long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that the President of Beam Therapeutics has been granted additional equity as part of their compensation package, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to attract and retain top talent.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedule of four years is fairly standard for RSU grants.

Stakeholder Impact

• The transaction aligns the executive's interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Giuseppe Ciaramella, Beam Therapeutics, Restricted Stock Units, Equity Incentive Plan, Insider Trading